繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

股东提醒:WeissLaw LLP调查Castlight Health,Inc.

2022-01-06 10:50

NEW YORK, Jan. 5, 2022 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Castlight Health, Inc. ("Castlight" or the "Company") (NYSE: CSLT), in connection with the proposed acquisition of the Company by Vera Whole Health, Inc. ("Vera") via a tender offer. Under the terms of the acquisition agreement, the Company's shareholders will receive $2.05 per share in cash for each share of Castlight common stock that they hold. The transaction is valued at approximately $370 million.

If you own Castlight shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:


Or please contact:
Joshua Rubin, Esq.
WeissLaw LLP
305 Broadway, 7th Floor
New York, NY 10007
(212) 682-3025
(888) 593-4771
[email protected]

WeissLaw LLP is investigating whether (i) Castlight's board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $2.05 per-share offer price adequately compensates Castlight's shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected]

SOURCE WeissLaw LLP

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。